Cabometyx plus Tecentriq led to improved progression-free survival compared with novel hormonal therapy in patients with metastatic castration-resistant prostate cancer.
Early lung-specific response to atezolizumab plus bevacizumab was associated with longer overall survival in patients with hepatocellular carcinoma with pulmonary metastases.
Drug treatment times for some NHS cancer patients will be slashed by up to three quarters, thanks to an anti-cancer injection that takes as little as seven minutes to administer.